CareDx reported that elevated AlloSure Kidney results in some patients were linked to nearly 3 times the risk of poor transplant outcomes. This supports the test's value for doctors, though the report gives no sales or hospital-use figures.
The findings give doctors another reason to consider AlloSure Kidney when watching for transplant rejection. That may help CareDx's test stand out, but the report does not show whether more hospitals will use it or whether sales will rise.
Follow CareDx (CDNA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CDNA